[
  {
    "ts": null,
    "headline": "A First Take On CG Oncology",
    "summary": "CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.",
    "url": "https://finnhub.io/api/news?id=1a6cc91e0715e5e770fc0e23f70a2b35b26914926f44eecb335d62f79b4b39ba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736528174,
      "headline": "A First Take On CG Oncology",
      "id": 132371715,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.",
      "url": "https://finnhub.io/api/news?id=1a6cc91e0715e5e770fc0e23f70a2b35b26914926f44eecb335d62f79b4b39ba"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
    "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=3a40e13c89682c41f6b9401ae7498df4df4a03772443cfeaea0d3bf33825b068",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736526720,
      "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "id": 132408143,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=3a40e13c89682c41f6b9401ae7498df4df4a03772443cfeaea0d3bf33825b068"
    }
  },
  {
    "ts": null,
    "headline": "4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025",
    "summary": "These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.",
    "url": "https://finnhub.io/api/news?id=fb725990662e539a6f7031711ea8aa58c87bab073cf24e1405561494be953ab8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736517600,
      "headline": "4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025",
      "id": 132364471,
      "image": "https://g.foolcdn.com/editorial/images/802810/2025-dividends.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.",
      "url": "https://finnhub.io/api/news?id=fb725990662e539a6f7031711ea8aa58c87bab073cf24e1405561494be953ab8"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab",
    "summary": "JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.",
    "url": "https://finnhub.io/api/news?id=eb2efdeedf1390cd72566f8fd3d2da199e314d2dc79fc0cb6e63f7ee8fa9d2ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736515440,
      "headline": "FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab",
      "id": 132366956,
      "image": "https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.",
      "url": "https://finnhub.io/api/news?id=eb2efdeedf1390cd72566f8fd3d2da199e314d2dc79fc0cb6e63f7ee8fa9d2ba"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter",
    "summary": "Media contact: Diane Pressman Dpressm1@its.jnj.com Anna Loring Aloring1@its.jnj.com ...",
    "url": "https://finnhub.io/api/news?id=1791a570c717d0ecbe613c12d5d80c23ff2f04be7839e0521343e326e992f241",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736506929,
      "headline": "Johnson & Johnson : MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter",
      "id": 132364365,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Media contact: Diane Pressman Dpressm1@its.jnj.com Anna Loring Aloring1@its.jnj.com ...",
      "url": "https://finnhub.io/api/news?id=1791a570c717d0ecbe613c12d5d80c23ff2f04be7839e0521343e326e992f241"
    }
  },
  {
    "ts": null,
    "headline": "J&J: obtains CE certification for a catheter",
    "summary": "Johnson & Johnson MedTech announces that it has obtained European CE certification for its Dual Energy Thermocool Hermocool Smarttouch SF catheter, designed for the treatment of cardiac arrhythmias....",
    "url": "https://finnhub.io/api/news?id=78c9c2ec5e5a7b03135084a2c58c6ef8dbf43f632e14d1ddd122eb60391525fb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736505788,
      "headline": "J&J: obtains CE certification for a catheter",
      "id": 132364173,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson MedTech announces that it has obtained European CE certification for its Dual Energy Thermocool Hermocool Smarttouch SF catheter, designed for the treatment of cardiac arrhythmias....",
      "url": "https://finnhub.io/api/news?id=78c9c2ec5e5a7b03135084a2c58c6ef8dbf43f632e14d1ddd122eb60391525fb"
    }
  },
  {
    "ts": null,
    "headline": "2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid",
    "summary": "Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry.",
    "url": "https://finnhub.io/api/news?id=a7234cce75a4f1078798ff03d4722b5d7980fb5b1492bf26ac63487fa88825c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736502660,
      "headline": "2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid",
      "id": 132364600,
      "image": "https://g.foolcdn.com/editorial/images/803256/nyse-floor-trader-stock-market-invest-buy-sell-fed-wall-street-getty.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry.",
      "url": "https://finnhub.io/api/news?id=a7234cce75a4f1078798ff03d4722b5d7980fb5b1492bf26ac63487fa88825c8"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis",
    "summary": "SPRING HOUSE - Johnson & Johnson today announced the nipocalimab Biologics License Application received Priority Review designation from the U.S. Food and Drug Administration for the treatment of...",
    "url": "https://finnhub.io/api/news?id=82b159f1881f2d0a81df46dd9ea8c83dd6bfbdc9a0dcfaf148117a172ee7751d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736498532,
      "headline": "Johnson & Johnson - Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis",
      "id": 132362897,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SPRING HOUSE - Johnson & Johnson today announced the nipocalimab Biologics License Application received Priority Review designation from the U.S. Food and Drug Administration for the treatment of...",
      "url": "https://finnhub.io/api/news?id=82b159f1881f2d0a81df46dd9ea8c83dd6bfbdc9a0dcfaf148117a172ee7751d"
    }
  },
  {
    "ts": null,
    "headline": "DLN: Dividend ETF Leading Its Competitors",
    "summary": "WisdomTree U.S. LargeCap Dividend Fund ETF provides value with 300 dividend stocks. Read why DLN is better for total return, despite lower yields and growth.",
    "url": "https://finnhub.io/api/news?id=9cd4e679d4cd2800d68ea88d78682a5d4a853aa9ce1e4eacfbc8e10e73525029",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736496000,
      "headline": "DLN: Dividend ETF Leading Its Competitors",
      "id": 132362585,
      "image": "https://media.gettyimages.com/id/sb10064568u-001/photo/cyclists-racing-side-view.jpg?b=1&s=612x612&w=0&k=20&c=mEo64eDNGUpi9QAEQgRUluiT__WYX8NGoEt6t8D26hw=",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "WisdomTree U.S. LargeCap Dividend Fund ETF provides value with 300 dividend stocks. Read why DLN is better for total return, despite lower yields and growth.",
      "url": "https://finnhub.io/api/news?id=9cd4e679d4cd2800d68ea88d78682a5d4a853aa9ce1e4eacfbc8e10e73525029"
    }
  }
]